



PATENT
Customer Number 22,852
Attorney Docket No.: 3495.0174-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In appln. of Laurent COEN et al.)
Serial No.: 10/662,808) Group Art Unit: Not yet assigned
Filed: September 16, 2003) Examiner: Not yet assigned

For: **IN VIVO MODULATION OF NEURONAL TRANSPORT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed within three months of the filing date of the above-referenced application. A copy of WO 99/09057 is attached. Copies of the remaining listed documents were previously submitted or cited by the Patent Office in prior application Serial Nos. 09/129,368, filed August 5, 1998, and 09/816,467, filed March 26, 2001, upon which applicants rely for the benefits provided in 35 U.S.C. § 120.

CA 1152493 claims priority to the same French priority document, FR 7929289, as EP 0030496, and is believed to represent an English translation of EP 0030496.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Laurent COEN et al.
S.N. 10/662,808

Atty. Docket No. 3495.0174-02

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 
Timothy B. Donaldson
Reg. No. 43,592

Date: November 24, 2003

Tel: (202) 408-4058
Fax: (202) 408-4400
E-mail: Timothy.Donaldson@finnegan.com


FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

605593_1

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No. 3495.0174-02	Serial No. 10/662,808
Applicant Laurent COEN et al.	
Filing Date September 16, 2003	Group Art Unit: Not yet assigned



U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,762,926	06/09/98	Gage et al.			
	4,594,336	06/10/86	Bizzini			
	4,479,940	10/30/84	Bizzini			
	5,728,399	03/17/98	Wu et al.			
	5,728,383	03/17/98	Johnson et al.			
	5,780,024	07/14/98	Brown et al.			
	5,840,540	11/98	George-Hyslop et al.			
	5,082,670	01/21/92	Gage et al.			
	5,580,859	12/03/96	Felgner et al.			
	5,589,466	12/31/96	Felgner et al.			
	5,643,578	07/01/97	Robinson et al.			
	6,159,948	12/12/00	Robertson et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub Class	Translation Yes or No
	0 030 496	06/17/81	EPO			
	1152493	08/23/83	Canada			
	1178949	12/04/84	Canada			
	WO 99/09057	02/25/99	PCT			

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No.	3495.0174-02	Serial No.	10/662,808
Applicant	Laurent COEN et al.		
Filing Date	September 16, 2003	Group Art Unit:	Not yet assigned

OTHER DOCUMENTS - (Including Author, Title, Date, Pertinent Pages, Etc.)	
	U.S. Patent Application Serial No. 09/501,787 of Coen et al.
	Erdmann et al., "Intraaxonal and Extraaxonal Transport of ¹²⁵ I-Tetanus Toxin in Early Local Tetanus," <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> , 290, pp. 357-373 (1975).
	Price et al., "Tetanus Toxin: Direct Evidence for Retrograde Intraaxonal Transport," <i>Science</i> , Vol. 188, pp. 945-947 (1975).
	Stockel et al., "Comparison Between the Retrograde Axonal Transport of Nerve Growth Factor and Tetanus Toxin in Motor, Sensory and Adrenergic Neurons," <i>Brain Research</i> , 99, pp. 1-16 (1975).
	Schwab et al., "Electron Microscopic Evidence for a Transsynaptic Migration of Tetanus Toxin in Spinal Cord Motoneurons: An Autoradiographic and Morphometric Study," <i>Brain Research</i> , 105, pp. 213-227 (1976).
	Helting et al., "Structure of Tetanus Toxin," <i>The Journal of Biological Chemistry</i> , 252, (1), pp. 187-193 (1977).
	Eisel et al., "Tetanus Toxin: Primary Structure, Expression in <i>E. coli</i> , and Homology with Botulinum Toxins," <i>The EMBO Journal</i> , 5, (10), pp. 2495-2502 (1986).
	Francis et al., "CuZn Superoxide Dismutase (SOD-1): Tetanus Toxin Fragment C Hybrid Protein for Targeted Delivery of SOD-1 to Neuronal Cells," <i>The Journal of Biological Chemistry</i> , 270, (25), pp. 15434-15442 (1995).
	Kuypers et al., "Viruses as Transneuronal Tracers," <i>TINS</i> , 13, (2), PP. 71-75 (1990).
	Figueiredo et al., "Delivery of Recombinant Tetanus-Superoxide Dismutase Proteins to Central Nervous System Neurons by Retrograde Axonal Transport," <i>Experimental Neurology</i> , 145, pp. 546-554 (1997).
	Beaude et al., "Retrograde Axonal Transport of an Exogenous Enzyme Covalently Linked to B-II _b Fragment of Tetanus Toxin," <i>Biochem. J.</i> , 271, pp. 87-91 (1990).
	Fishman et al., "Enhanced CNS Uptake of Systemically Administered Proteins Through Conjunction with Tetanus C-fragment," <i>Journal of the Neurological Sciences</i> , 98, pp. 311-325 (1990).

Examiner	Date Considered
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No.	3495.0174-02	Serial No.	10/662,808
Applicant	Laurent COEN et al.		
Filing Date	September 16, 2003	Group Art Unit:	Not yet assigned

OTHER DOCUMENTS - CONT'D. (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>OTYPE NOV 24 2003 PATENT & TRADEMARK OFFICE 863</i>	Orkin et al., <i>Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy</i> (December 1995).
	Montecucco et al., "Structure and Function of Tetanus and Botulinum Nerotoxins," <i>Quarterly Reviews of Biophysics</i> , 28 pp. 423-472 (1995).
	Hazinski et al., <i>Am. J. Respir. Cell Mol. Biol.</i> , Vol. 4(3), pp. 206-209 (1991).
	P. Boucher et al., "Neutralizing Antibodies and Immunoprotection Against Pertussis and Tetanus Obtained by Use of a Recombinant Pertussis Toxin-Tetanus Toxin Fusion Protein," <i>Infection and Immunity</i> , Vol. 62, No. 2, pp. 449-456 (1994)
	J. Francis et al., "CuZn Superoxide Dismutase (SOD-1):Tetanus Toxin Fragment C Hybrid Protein for Targeted Delivery of SOD-1 to Neuronal Cells," <i>J. Biological Chemistry</i> , Vol. 270, No. 25, pp. 15434-15442 (June 23, 1995).
	N. Fairweather et al., "Immunization of Mice Against Tetanus With Fragments of Tetanus Toxin Synthesized in <i>Escherichia coli</i> ," <i>Infection and Immunity</i> , Vol. 55, No. 11, pp. 2541-2545 (Nov. 1987).
	P. Liston et al., "Suppression of Apoptosis in Mammalian Cells by NAIP and a Related Family of IAP Genes," <i>Nature</i> , Vol. 379, pp. 349-353 (January 25, 1996).
	G.P. Mueller, ARO-27890.1-LS, Order No. AD-A290 501, NTIS, p. 1-15 (1994)
	Hohne-Zell et al., <i>FEBS Letters</i> , Vol. 336, No. 1, p. 175-180 (1993)
	J. Rudinger, "Peptide Hormones", edited by Parsons, J., University Park Press, Baltimore, p. 1-7 (1976)
	Kaye et al. <i>PNAS, USA</i> , Vol. 87, pp. 6922-6926 (1990)

Examiner	Date Considered
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce